Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase l study of FG-3165 in patients with solid tumors

Next Previous
Trial Profile

A Phase l study of FG-3165 in patients with solid tumors

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FG 3165 (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use

Most Recent Events

  • 07 Jun 2024 According to FibroGen, Regeneron Pharmaceuticals media release, this trial is expected to initiate in the second half of 2024
  • 07 Jun 2024 New trial record
  • 03 Jun 2024 According to FibroGen media release, the U.S. Food and Drug Administration (FDA) has cleared Investigational New Drug (IND) of FG-3165, a galectin-9 (Gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression. Toxicology material as well as GMP material for the this Phase 1 clinical trial was manufactured in partnership with Just-Evotec Biologics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top